P
Prasert Lertsanguansinchai
Researcher at King Chulalongkorn Memorial Hospital
Publications - 22
Citations - 518
Prasert Lertsanguansinchai is an academic researcher from King Chulalongkorn Memorial Hospital. The author has contributed to research in topics: Chemoradiotherapy & Radiation therapy. The author has an hindex of 10, co-authored 19 publications receiving 443 citations. Previous affiliations of Prasert Lertsanguansinchai include Chulalongkorn University.
Papers
More filters
Journal ArticleDOI
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
Vicharn Lorvidhaya,Imjai Chitapanarux,Supatra Sangruchi,Prasert Lertsanguansinchai,Yongyut Kongthanarat,Saipin Tangkaratt,Ekachai Visetsiri +6 more
TL;DR: Conurrent chemotherapy, mitomycin C, and 5-FU together with conventional RT showed an improved DFS rate when compared with conventionalRT alone in patients with locally advanced carcinoma of the cervix, and there were no increases in late side effects.
Journal ArticleDOI
Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.
Prasert Lertsanguansinchai,Chawalit Lertbutsayanukul,Kanjana Shotelersuk,Chonlakiet Khorprasert,Prayuth Rojpornpradit,Taywin Chottetanaprasith,Apiradee Srisuthep,Sivalee Suriyapee,Chotika Jumpangern,Damrong Tresukosol,Chulee Charoonsantikul +10 more
TL;DR: Comparable outcomes were demonstrated between LDR and HDR intracavitary brachytherapy, and the high number of distant failure suggests that other modalities such as systemic concurrent or adjuvant chemotherapy might lower this high recurrence, especially in Stage IIB and IIIB patients.
Journal ArticleDOI
A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.
Siriwan Tangjitgamol,Ekkasit Tharavichitkul,Chokaew Tovanabutra,Kanisa Rongsriyam,Tussawan Asakij,Kannika Paengchit,Jirasak Sukhaboon,Somkit Penpattanagul,Apiradee Kridakara,Jitti Hanprasertpong,Kittisak Chomprasert,Sirentra Wanglikitkoon,Thiti Atjimakul,Piyawan Pariyawateekul,Kanyarat Katanyoo,Prapai Tanprasert,Wanwipa Janweerachai,Duangjai Sangthawan,Jakkapan Khunnarong,Taywin Chottetanaprasith,Busaba Supawattanabodee,Prasert Lertsanguansinchai,Jatupol Srisomboon,Wanrudee Isaranuwatchai,Wanrudee Isaranuwatchai,V. Lorvidhaya +25 more
TL;DR: ACT with paclitaxel plus carboplatin after CCRT did not improve response rate and survival compared to C CRT alone, and only significant decrease of systemic recurrences with ACT was observed, but not overall or loco-regional failure.
Journal ArticleDOI
Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: A multicenter, randomized, two-arm, open-label trial
Vutisiri Veerasarn,Chonlakiet Khorprasert,Vicharn Lorvidhaya,Supatra Sangruchi,Thanatip Tantivatana,Ladawan Narkwong,Yongyut Kongthanarat,Imjai Chitapanarux,Chanawat Tesavibul,Apichart Panichevaluk,Sirisak Puribhat,Somphob Sangkittipaiboon,Lak Sookpreedee,Prasert Lertsanguansinchai,Pramook Phromratanapongse,Poonkiat Rungpoka,Supamitr Trithratipvikul,Bannakij Lojanapiwat,Sathit Ruangdilokrat,Pichai Ngampanprasert +19 more
TL;DR: WF10 therapy is a safe, non-invasive and convenient method in the management of late hemorrhagic radiation cystitis and has significantly reduced recurrence of objective hematuria, compared to standard treatment alone, during a one year follow up.
Journal ArticleDOI
A randomized phase III trial of concurrent chemoradiotherapy in locally advanced cervical cancer: preliminary results.
Vutisiri Veerasarn,Vicharn Lorvidhaya,Pimkhuan Kamnerdsupaphon,Nan Suntornpong,Supatra Sangruchi,Prasert Lertsanguansinchai,Chonlakiet Khorprasert,Lak Sookpreedee,Suthipol Udompunturak +8 more
TL;DR: Conurrent chemoradiation by Tegafur-Uracil and carboplatin showed no difference in tumor response rate or treatment toxicity compared to carboplatis alone, and the combination drugs might have benefit in poor prognostic patients such as the baseline Hb <10 gm/dL.